Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Proteus Biomedical has entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize pharmaceutical products that incorporate Proteus’ novel sensor-based technologies in the field of organ transplantation.
Subscribe to our email newsletter
Novartis also receives certain option rights in cardiovascular and oncology product applications, and rights to use Proteus technologies in its clinical development of pharmaceutical products.
Under the terms of the agreement, Novartis will make upfront cash and equity investments in Proteus totaling $24m. Proteus would also receive royalties on worldwide net sales of any Novartis products incorporating its sensor-based technology.
Andrew Thompson, president and chief executive officer of Proteus, said: “We believe that Novartis is a global leader in organ transplant drug development and marketing, which makes it an excellent collaborator to advance sensor-based pharmaceutical treatment systems. We have a great opportunity together to bring a new type of pharmaceutical product to market that could aid patients, their families and physicians to attain maximum adherence with pharmaceutical therapy.”